← PALISADE BIO, INC. (PALI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
PALISADE BIO, INC. (PALI)
Biological Products, (No Diagnostic Substances) · market cap $284M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Palisade Bio (PALI) is a clinical-stage biotech with a market cap of ~$342M and a single disclosed lead asset, LB1148, currently in Phase 2 development for postoperative ileus. The company carries $132.6M in cash (roughly 102 months of runway) and generates no revenue, burning approximately $10M in R&D annually.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| LB1148 | Phase 2 | Ileus |
Price & technical context
3-month
-31.9%
6-month
-23.9%
12-month
+66.3%
52-wk range
$1.31–$2.80
vs 50-day MA
-26.0%
vs 200-day MA
-25.4%
Realized vol
100.0%
Max drawdown
-86.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PALI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.